Methylene Chloride

Methylene Chloride

SCHEMBL5133360

CC(=O)CC(Cl)Cl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL4557546 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL2391146 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL2456472 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL6704394 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL861591 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL4304807 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL3630221 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL7695098 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL1395290 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1
Methylene Chloride SCHEMBL5091282 1.00 ALDH1A1 (0.48) ALDH1A1TDP1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108503672-B Osmium peroxide complex and preparation method and application thereof 厦门大学 2020-01-10 CN disclosed
CN-108503672-A Osmium peroxide complex and its preparation method and application 厦门大学 2018-09-07 CN disclosed
CN-106146566-A Miscellaneous fused ring compound of osmium and preparation method thereof, the composition containing this compound and application 厦门大学 2016-11-23 CN disclosed
US-20080039342-A1 PROCESS FOR TRANSITION METAL-CATALYZED ELECTROCHEMICAL ALLYLIC ALKYLATION ON AN ELECTRODE ARRAY DEVICE COMBIMATRIX CORPORATION (US) 2008-02-14 US disclosed
US-7226578-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SHERING AG (DE) 2007-06-05 US disclosed
US-6916461-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2005-07-12 US disclosed
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-07 US disclosed
CN-1203898-C Perfluoroalkyl-containing metal complexes, its preparing method and use in NMR diagnostics SCHRING AG (DE) 2005-06-01 CN disclosed
US-6825194-B2 AN 11,12-(-N=C(=O,S OR NH)-NH-)CAMPTOTHECIN DERIVATIVE OR AN 11,12-(-N=CH-NH-)CAMPTOTHEDIN DERIVATIVE; ANTICARCINOGENIC, -TUMOR AND -PROLIFERATIVE AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-11-30 US disclosed
US-20030232012-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2003-12-18 US disclosed
US-20030144304-A1 Novel hexacyclic compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-07-31 US disclosed
US-6468502-B1 PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA SCHERING AKTIENGESELLSCHAFT (DE) 2002-10-22 US disclosed
US-6180113-B1 USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AG (DE) 2001-01-30 US disclosed
CN-1209754-A Perfluoroalkyl-containing metal complexes, its preparing method and use in NMR diagnostics SCHRING AG (DE) 1999-03-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis FABP1, FLOT1, AFF1 ALDH1A1 4185/4885TDP1 3498/4885TRPA1 1830/4885
US-20030144304-A1 Novel hexacyclic compounds CYP11B1, CYP11B2, CYP51A1 ALDH1A1 499/4885TDP1 3391/4885TRPA1 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.